Drug Profile
Research programme: allogenic stem cell therapies - SanBio
Latest Information Update: 17 May 2022
Price :
$50
*
At a glance
- Originator SanBio
- Class Stem cell therapies
- Mechanism of Action Cell replacements; Nerve growth factor modulators; Nerve growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Peripheral nerve injuries
- No development reported Multiple sclerosis; Muscular dystrophies; Spinal cord injuries
Most Recent Events
- 17 May 2022 Preclinical development for Peripheral nerve injuries is ongoing in USA (SanBio Pipeline, May 2022)
- 28 Feb 2020 No recent reports of development identified for preclinical development in Muscular-dystrophies in USA (Injection)
- 28 Feb 2018 Preclinical development in Muscular-dystrophies is ongoing in USA (Injection) (SanBio pipeline,February 2018)